The U.S. oncology molecular diagnostics market size is calculated at USD 880 million in 2025 and is forecasted to reach around USD 2,500 million by 2034, accelerating at a CAGR of 12.21% from 2025 to 2034. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: U.S. Oncology Molecular Diagnostics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: U.S Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. U.S. Oncology Molecular Diagnostics Market Revenue and Volume, by Type
8.1.1 Breast Cancer
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Liver Cancer
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Prostate Cancer
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Colorectal Cancer
8.1.4.1. Market Revenue and Volume Forecast
8.1.5. Cervical Cancer
8.1.5.1. Market Revenue and Volume Forecast
8.1.6. Lung Cancer
8.1.6.1. Market Revenue and Volume Forecast
8.1.7. Blood Cancer
8.1.7.1. Market Revenue and Volume Forecast
8.1.8. Kidney Cancer
8.1.8.1. Market Revenue and Volume Forecast
8.1.9. Other Cancer
8.1.9.1. Market Revenue and Volume Forecast
9.1. U.S. Oncology Molecular Diagnostics Market Revenue and Volume, by Technology
9.1.1. PCR
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Sequencing
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. In Situ Hybridization
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. INAAT
9.1.4.1. Market Revenue and Volume Forecast
9.1.5. Chips and Microarrays
9.1.5.1. Market Revenue and Volume Forecast
9.1.6. Mass Spectrometry
9.1.56.1. Market Revenue and Volume Forecast
9.1.7. TMA
9.1.7.1. Market Revenue and Volume Forecast
9.1.8. Others
9.1.8.1. Market Revenue and Volume Forecast
10.1. U.S. Oncology Molecular Diagnostics Market Revenue and Volume, by Product
10.1.1. Reagents
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Instruments
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Others
10.1.3.1. Market Revenue and Volume Forecast
11.1. U.S
11.1.1. Market Revenue and Volume Forecast, by Type
11.1.2. Market Revenue and Volume Forecast, by Technology
11.1.3. Market Revenue and Volume Forecast, by Product
12.1. Roche Diagnostics
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Abbott Laboratories
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Thermo Fisher Scientific Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Illumina, Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bio-Rad Laboratories, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Myriad Genetics, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Agilent Technologies, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Danaher Corporation (Cepheid)
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Hologic, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Foundation Medicine, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample